BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 31889532)

  • 1. Could cathepsin-k be a driver of the myofibroblastic differentiation observed in dermatofibroma, atypical fibroxanthoma and pleomorphic dermal sarcoma?
    Ricci C; De Leo A; Dika E; Lambertini M; Veronesi G; Corti B
    Acta Histochem; 2020 Feb; 122(2):151498. PubMed ID: 31889532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of CD10 and procollagen 1 expression in atypical fibroxanthoma and dermatofibroma.
    de Feraudy S; Mar N; McCalmont TH
    Am J Surg Pathol; 2008 Aug; 32(8):1111-22. PubMed ID: 18545147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Fibrohistiocytic tumors of the skin: a heterogeneous group of superficially located mesenchymal neoplasms].
    Mentzel T
    Pathologe; 2015 Feb; 36(1):79-88. PubMed ID: 25589356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microphthalmia-associated transcription factor (MiTF): Promiscuous staining patterns in fibrohistiocytic lesions is a potential pitfall.
    Mohanty SK; Sharma S; Pradhan D; Kandukuri SR; Farahani N; Barry C; Wu JM; Frishberg D; Balzer B
    Pathol Res Pract; 2018 Jun; 214(6):821-825. PubMed ID: 29773427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Fibrohistiocytic skin tumors].
    Hügel H
    J Dtsch Dermatol Ges; 2006 Jul; 4(7):544-55. PubMed ID: 16827912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High proliferative activity excludes dermatofibroma: report of the utility of MIB-1 in the differential diagnosis of selected fibrohistiocytic tumors.
    Hanly AJ; Jordà M; Elgart GW; Badiavas E; Nassiri M; Nadji M
    Arch Pathol Lab Med; 2006 Jun; 130(6):831-4. PubMed ID: 16740036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PRAME immunohistochemistry in soft tissue tumors and mimics: a study of 350 cases highlighting its imperfect specificity but potentially useful diagnostic applications.
    Cammareri C; Beltzung F; Michal M; Vanhersecke L; Coindre JM; Velasco V; Le Loarer F; Vergier B; Perret R
    Virchows Arch; 2023 Aug; 483(2):145-156. PubMed ID: 37477762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cutaneous mesenchymal tumours: an update.
    Mentzel T
    Pathology; 2014 Feb; 46(2):149-59. PubMed ID: 24378387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mast cells in cutaneous tumors: innocent bystander or maestro conductor?
    Biswas A; Richards JE; Massaro J; Mahalingam M
    Int J Dermatol; 2014 Jul; 53(7):806-11. PubMed ID: 23621615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HMB-45 expression in a clear cell variant of atypical fibroxanthoma.
    Cai JP; Randall B
    J Cutan Pathol; 2006 Feb; 33(2):186-8. PubMed ID: 16420318
    [No Abstract]   [Full Text] [Related]  

  • 11. Prominent myofibroblastic differentiation. A pitfall in the diagnosis of dermatofibroma.
    Zelger BW; Zelger BG; Rappersberger K
    Am J Dermatopathol; 1997 Apr; 19(2):138-46. PubMed ID: 9129698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pleomorphic dermal sarcoma in a man with HIV: report with next-generation sequencing analysis and review of the atypical fibroxanthoma/pleomorphic dermal sarcoma spectrum.
    Chen SX; Eichenfield DZ; Orme C; Hinds B
    Dermatol Online J; 2019 Nov; 25(11):. PubMed ID: 32045146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LN-2 (CD74). A marker to distinguish atypical fibroxanthoma from malignant fibrous histiocytoma.
    Lazova R; Moynes R; May D; Scott G
    Cancer; 1997 Jun; 79(11):2115-24. PubMed ID: 9179057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soft Tissue Special Issue: Cutaneous Pleomorphic Spindle Cell Tumors.
    Brenn T
    Head Neck Pathol; 2020 Mar; 14(1):109-120. PubMed ID: 31950467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conception and Management of a Poorly Understood Spectrum of Dermatologic Neoplasms: Atypical Fibroxanthoma, Pleomorphic Dermal Sarcoma, and Undifferentiated Pleomorphic Sarcoma.
    Soleymani T; Tyler Hollmig S
    Curr Treat Options Oncol; 2017 Aug; 18(8):50. PubMed ID: 28762020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD10, p63 and CD99 expression in the differential diagnosis of atypical fibroxanthoma, spindle cell squamous cell carcinoma and desmoplastic melanoma.
    Kanner WA; Brill LB; Patterson JW; Wick MR
    J Cutan Pathol; 2010 Jul; 37(7):744-50. PubMed ID: 20184665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increase of atypical fibroxanthoma and pleomorphic dermal sarcoma: a retrospective analysis of four German skin cancer centers.
    Kuntz T; Siebdrath J; Hofmann SC; Baltaci M; Schaller J; Hellmich M; von Goltzheim LS; Assaf C; Oellig F; Michalowitz AL; Helbig D; Kreuter A
    J Dtsch Dermatol Ges; 2022 Dec; 20(12):1581-1588. PubMed ID: 36442137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calponin and h-caldesmon expression in atypical fibroxanthoma and superficial leiomyosarcoma.
    Sakamoto A; Oda Y; Yamamoto H; Oshiro Y; Miyajima K; Itakura E; Tamiya S; Honda Y; Ishihara A; Iwamoto Y; Tsuneyoshi M
    Virchows Arch; 2002 Apr; 440(4):404-9. PubMed ID: 11956822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atypical fibroxanthoma/pleomorphic dermal sarcoma of the scalp with aberrant expression of HMB-45: a pitfall in dermatopathology.
    Piras V; Ferreli C; Atzori L; Pinna G; Pilloni L
    Pathologica; 2020 Jun; 112(2):105-109. PubMed ID: 32760054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pigmented atypical fibroxanthoma, a dermatofibroma variant?
    Zelger B
    Am J Dermatopathol; 2004 Feb; 26(1):84-6; author reply 86-7. PubMed ID: 14726831
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.